Alzheimer’s-associated enzyme can disrupt neural activity in the brain

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital

MGH study could explain incidence of seizures in Alzheimer’s patients
An enzyme involved in the formation of the amyloid-beta protein associated with Alzheimer’s disease can also alter the mechanism by which signals are transmitted between brain cells, the disruption of which can cause seizures. These findings from researchers at the MassGeneral Institute for Neurodegenerative Disorders (MGH-MIND) may explain the increased incidence of seizures in Alzheimer’s patients and suggest that potential treatments that block this enzyme – called beta-secretase or BACE – may alleviate their occurrence. The report will appear in the journal Nature Cell Biology and is receiving early online release.

“We have found a molecular pathway by which BACE can modulate the activity of sodium channels on neuronal cell membranes,” says study leader Dora Kovacs, PhD, director of the Neurobiology of Disease Laboratory in the Genetics and Aging Research Unit at MGH-MIND. “That implies that elevated BACE activity may be responsible for the seizures frequently observed in Alzheimer’s patients.”

Alzheimer’s disease is characterized by plaques within the brain of the toxic amyloid-beta protein. Amyloid-beta is formed when the larger amyloid precursor protein (APP) is clipped by two enzymes – BACE and gamma-secretase – which releases the amyloid-beta fragment.

Signaling impulses in nerve cells are transmitted via voltage-gated sodium channels, structures on the cell membrane that transmit electrochemical signal by admitting charged sodium particles into the cell’s interior. Sodium channels consist of an alpha subunit, which makes up the body of the channel, and one or two beta subunits that help to regulate the channels’ activity.

Previous studies from Kovacs’ team and others showed that the BACE and gamma-secretase enzymes that release amyloid-beta from APP also act on the beta2 subunit of neuronal sodium channels. The current study was designed to examine how this processing of the beta2 subunit may alter neuronal function.

Lead author Doo Yeon Kim, PhD, and colleagues first confirmed that the beta2 subunit, similar to APP, can be acted on by BACE and gamma-secretase, releasing a portion of the beta2 molecule from the cell membrane. A series of experiments using brain tissue from animal models and from Alzheimer’s patients revealed the following series of cellular events: Elevated levels of the free beta2 segment within the cell appear to increase production of the alpha subunits, but those molecules are not incorporated into new sodium channels on the cell surface. The resulting deficit of membrane sodium channels inhibits the passage of neuronal signals into and through the cells.

Neuronal sodium-channel dysfunction is known to cause seizures in both mice and humans. In a supplement to the current paper the investigators present evidence that sodium channel metabolism is altered in the brains of Alzheimer’s patients compared with non-demented individuals of similar age.

“Our study suggests that the BACE inhibitors currently being developed to reduce amyloid-beta generation in Alzheimer’s disease patients may also help prevent seizures by alleviating disrupted neural activity,” Kovacs explains. “However, complete inhibition of BACE activity could interfere with the enzyme’s normal regulation of sodium channels, so therapeutic strategies using those inhibitors will need to be carefully designed.” Kovacs is an associate professor of Neurology at Harvard Medical School.

###
The Kovacs team hopes to continue investigating how BACE-induced changes in sodium channel metabolism contribute to other Alzheimer’s symptoms and to additional neuronal cell activity. Co-first authors of the Nature Cell Biology paper are Doo Yeon Kim, PhD, and Bryce Carey, of MGH-MIND. Additional co-authors are Laura Ingano, Mary Wertz, and Warren Pettingell, MGH-MIND; Haibin Wang, MD, PhD, Alexander Binshtok, PhD, and Clifford Woolf, PhD, MGH Anesthesia-Critical Care; Ping He, PhD, Sun Health Research Institute; and Virginia Lee, PhD, University of Pennsylvania School of Medicine. The study was supported by grants from the National Institutes of Health, National Institute of Aging, and the John D. French Alzheimer’s Foundation.

Massachusetts General Hospital, established in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $500 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, systems biology, transplantation biology and photomedicine. MGH and Brigham and Women’s Hospital are founding members of Partners HealthCare HealthCare System, a Boston-based integrated health care delivery system.

Global Health Vision

Source

Advertisements